JP2008510783A - ４−ヘテロアリールメチル置換フタラジノン誘導体 - Google Patents

４−ヘテロアリールメチル置換フタラジノン誘導体 Download PDF

Info

Publication number
JP2008510783A
JP2008510783A JP2007528985A JP2007528985A JP2008510783A JP 2008510783 A JP2008510783 A JP 2008510783A JP 2007528985 A JP2007528985 A JP 2007528985A JP 2007528985 A JP2007528985 A JP 2007528985A JP 2008510783 A JP2008510783 A JP 2008510783A
Authority
JP
Japan
Prior art keywords
optionally substituted
group
compound
alkyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007528985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008510783A5 (enExample
Inventor
ジャヴィド，モハメッド，ハシム
スミス，グレーム，キャメロン．マーレイ
マーティン，ニアル，モリソン，バール
ゴメス，シルヴィー
ロウ，ヴィンセント，ジュニア，ミン，ライ
コッククロフト，シャオ−リン，ファン
フォルト，ステファノ
メニアー，キース，アラン
マシューズ，イアン，ティモシー，ウィリアム
Original Assignee
クドス ファーマシューティカルズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0419072.4A external-priority patent/GB0419072D0/en
Application filed by クドス ファーマシューティカルズ リミテッド filed Critical クドス ファーマシューティカルズ リミテッド
Publication of JP2008510783A publication Critical patent/JP2008510783A/ja
Publication of JP2008510783A5 publication Critical patent/JP2008510783A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007528985A 2004-08-26 2005-08-26 ４−ヘテロアリールメチル置換フタラジノン誘導体 Pending JP2008510783A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0419072.4A GB0419072D0 (en) 2004-08-26 2004-08-26 Phthalazinone derivatives
US60495604P 2004-08-27 2004-08-27
PCT/GB2005/003343 WO2006021801A1 (en) 2004-08-26 2005-08-26 4-heteroarylmethyl substituted phthalazinone derivatives

Publications (2)

Publication Number Publication Date
JP2008510783A true JP2008510783A (ja) 2008-04-10
JP2008510783A5 JP2008510783A5 (enExample) 2008-09-04

Family

ID=35219560

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007528985A Pending JP2008510783A (ja) 2004-08-26 2005-08-26 ４−ヘテロアリールメチル置換フタラジノン誘導体

Country Status (11)

Country Link
EP (1) EP1791827A1 (enExample)
JP (1) JP2008510783A (enExample)
KR (1) KR20070057859A (enExample)
AU (1) AU2005276229A1 (enExample)
BR (1) BRPI0514632A (enExample)
CA (1) CA2577191A1 (enExample)
IL (1) IL181408A0 (enExample)
MX (1) MX2007002318A (enExample)
NO (1) NO20071579L (enExample)
NZ (1) NZ553979A (enExample)
WO (1) WO2006021801A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544261A (ja) * 2010-12-02 2013-12-12 シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド 複素環誘導体、その合成法および医療用途
JP2014508168A (ja) * 2011-03-14 2014-04-03 エターニティ バイオサイエンス インコーポレイテッド キナゾリンジオン及びその使用
JP2014516989A (ja) * 2011-05-31 2014-07-17 ニューゲン セラピューティクス， インコーポレイテッド ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤
JP2018517763A (ja) * 2015-04-17 2018-07-05 上海匯倫生命科技有限公司 複素環イミダゾール類化合物、その医薬組成物及びその調製方法と用途
JP2024532845A (ja) * 2021-08-17 2024-09-10 インベンティスバイオ カンパニー リミテッド ピリダジノンまたはピリジノン化合物、その製造方法および用途

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
JP5271897B2 (ja) 2006-05-31 2013-08-21 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ ポリ（ＡＤＰ−リボース）ポリメラーゼ（ＰＡＲＰ）の阻害剤としての、ピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン及びピロロ［１，２−ｄ］［１，２，４］トリアジン−１（２Ｈ）−オン誘導体
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2009034326A1 (en) * 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
JP5758630B2 (ja) 2007-11-15 2015-08-05 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Ｐａｒｐ阻害剤としてのピリダジノン誘導体
AR070221A1 (es) * 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
ES2551557T3 (es) 2008-12-19 2015-11-19 Boehringer Ingelheim International Gmbh Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC
PL2513093T3 (pl) 2009-12-17 2015-03-31 Centrexion Therapeutics Corp Nowi antagoniści receptora CCR2 i ich zastosowanie
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141474A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
EP2571870B1 (en) 2010-05-17 2015-01-21 Boehringer Ingelheim International GmbH Ccr2 antagonists and uses thereof
US9018212B2 (en) 2010-05-25 2015-04-28 Boehringer Ingelheim International Gmbh Pyridazine carboxamides as CCR2 receptor antagonists
JP5721242B2 (ja) 2010-06-01 2015-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２アンタゴニスト
WO2012014221A1 (en) 2010-07-27 2012-02-02 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
KR101242572B1 (ko) * 2010-10-12 2013-03-19 한국화학연구원 5-환 헤테로 아릴로 치환된 프탈라지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 약학적 조성물
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102964354B (zh) * 2012-11-16 2014-08-13 江苏先声药业有限公司 一类噻吩并咪唑衍生物及其应用
CN102977040B (zh) * 2012-11-20 2015-06-03 浙江工业大学 一种2-喹喔啉基二甲缩醛和2-喹喔啉基甲醛的合成方法
MX2015006780A (es) 2012-12-31 2015-08-06 Cadila Healthcare Ltd Derivados de ftalazin-1-(2h)-ona sustituida.
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
MX383744B (es) 2015-07-02 2025-03-14 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidin-1-il) (5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2h-piran-2-il) metilamino) pirimidin-4-il) metanona.
CN105384684B (zh) * 2015-12-16 2018-02-13 辽宁工程技术大学 一种2‑氰基‑6‑甲基吡啶的制备方法
CA3129516A1 (en) * 2018-02-28 2019-09-06 The Trustees Of The University Of Pennsylvania Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
US20220110936A1 (en) * 2019-02-02 2022-04-14 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Pharmaceutical composition for treatment of neurodegenerative diseases or diseases caused by abnormality of rna binding protein and applications thereof
TWI837403B (zh) 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6413073A (en) * 1987-05-02 1989-01-17 Asta Pharma Ag 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinone derivative, manufacture, antiasthmatic and antiallergic drug and manufacture of drug
JPH1045723A (ja) * 1996-05-30 1998-02-17 F Hoffmann La Roche Ag 新規なピリダジノン誘導体
WO2003070707A1 (en) * 2002-02-19 2003-08-28 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
WO2003093261A1 (en) * 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2004513121A (ja) * 2000-10-30 2004-04-30 クドス　ファーマシューティカルズ　リミテッド フタラジノン誘導体
JP2004528376A (ja) * 2001-05-08 2004-09-16 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害薬としてのイソキノリノン誘導体
WO2004080976A1 (en) * 2003-03-12 2004-09-23 Kudos Pharmaceuticals Limited Phthalazinone derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3813531A1 (de) * 1987-05-02 1988-11-10 Asta Pharma Ag Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate
HU228960B1 (hu) * 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6413073A (en) * 1987-05-02 1989-01-17 Asta Pharma Ag 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinone derivative, manufacture, antiasthmatic and antiallergic drug and manufacture of drug
JPH1045723A (ja) * 1996-05-30 1998-02-17 F Hoffmann La Roche Ag 新規なピリダジノン誘導体
JP2004513121A (ja) * 2000-10-30 2004-04-30 クドス　ファーマシューティカルズ　リミテッド フタラジノン誘導体
JP2004528376A (ja) * 2001-05-08 2004-09-16 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害薬としてのイソキノリノン誘導体
WO2003070707A1 (en) * 2002-02-19 2003-08-28 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
WO2003093261A1 (en) * 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2004080976A1 (en) * 2003-03-12 2004-09-23 Kudos Pharmaceuticals Limited Phthalazinone derivatives

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013544261A (ja) * 2010-12-02 2013-12-12 シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド 複素環誘導体、その合成法および医療用途
JP2014508168A (ja) * 2011-03-14 2014-04-03 エターニティ バイオサイエンス インコーポレイテッド キナゾリンジオン及びその使用
JP2014516989A (ja) * 2011-05-31 2014-07-17 ニューゲン セラピューティクス， インコーポレイテッド ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤
US11248013B2 (en) 2011-05-31 2022-02-15 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(ADP-ribose)polymerase
US12612425B2 (en) 2011-05-31 2026-04-28 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(ADP-ribose)polymerase
JP2018517763A (ja) * 2015-04-17 2018-07-05 上海匯倫生命科技有限公司 複素環イミダゾール類化合物、その医薬組成物及びその調製方法と用途
JP2024532845A (ja) * 2021-08-17 2024-09-10 インベンティスバイオ カンパニー リミテッド ピリダジノンまたはピリジノン化合物、その製造方法および用途

Also Published As

Publication number Publication date
CA2577191A1 (en) 2006-03-02
AU2005276229A1 (en) 2006-03-02
NZ553979A (en) 2009-05-31
KR20070057859A (ko) 2007-06-07
MX2007002318A (es) 2007-04-17
WO2006021801A1 (en) 2006-03-02
IL181408A0 (en) 2007-07-04
NO20071579L (no) 2007-05-29
BRPI0514632A (pt) 2008-06-17
EP1791827A1 (en) 2007-06-06

Similar Documents

Publication Publication Date Title
CN101048399B (zh) 4-杂芳基甲基取代的酞嗪酮衍生物
JP4268651B2 (ja) フタラジノン誘導体
MX2007002318A (es) Derivados de ftalazinona substituidos con 4-heteroarilmetilo.
EP2176237A1 (en) Phthalazinone derivatives as inhibitors of parp-1
KR20100016366A (ko) 프탈라지논 유도체 및 암 치료를 위한 약제로서의 이의 용도
JP2009512671A (ja) ４−ヘテロアリールメチル置換されたフタラジノン誘導体
JP2009541217A (ja) Ｐａｒｐ阻害剤としての２−オキシベンズアミド誘導体
JP2011510056A (ja) フタラジノン誘導体
JP2009539963A (ja) Ｐａｒｐ阻害剤
JP2008525411A (ja) Ｐａｒｐ阻害剤
JP2009539962A (ja) Ｐａｒｐ阻害剤としての２−オキシヘテロアリールアミド誘導体
KR20100059950A (ko) 프탈라지논 유도체
MX2008004913A (en) 4-heteroarymethyl substituted phthalazinone derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090107

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120327